Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report published on Monday. The brokerage issued a buy rating on the biotechnology company’s stock.

Other analysts have also recently issued reports about the company. HC Wainwright reduced their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Wells Fargo & Company reduced their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research note on Friday, March 21st. Guggenheim lowered their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a report on Wednesday, March 26th. Finally, Scotiabank decreased their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday, March 21st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1.83.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP opened at $0.24 on Monday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The firm has a market cap of $61.74 million, a PE ratio of -1.09 and a beta of 2.84. Adaptimmune Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.48. The company’s 50 day simple moving average is $0.40 and its 200-day simple moving average is $0.59.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The company had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. As a group, equities analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 19,146 shares during the period. Virtu Financial LLC lifted its position in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 21,769 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.